These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15615278)

  • 1. [The treatment with methylphenidate of demoralisation, apathy and hypoactive delirium in patients with somatic illness].
    Rikkert MG
    Ned Tijdschr Geneeskd; 2004 Nov; 148(48):2416; author reply 2416-7. PubMed ID: 15615278
    [No Abstract]   [Full Text] [Related]  

  • 2. [The treatment with methylphenidate of demoralisation, apathy and hypoactive delirium in patients with somatic illness].
    Geurts AC; Lem FC
    Ned Tijdschr Geneeskd; 2004 Nov; 148(48):2417; author reply 2417. PubMed ID: 15615279
    [No Abstract]   [Full Text] [Related]  

  • 3. [The treatment with methylphenidate of demoralisation, apathy and hypoactive delirium in patients with somatic illness].
    Meyers BJ; van Ojen RL
    Ned Tijdschr Geneeskd; 2004 Aug; 148(35):1738-41. PubMed ID: 15468905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study.
    Gagnon B; Low G; Schreier G
    J Psychiatry Neurosci; 2005 Mar; 30(2):100-7. PubMed ID: 15798785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylphenidate may treat apathy independent of depression.
    Padala PR; Petty F; Bhatia SC
    Ann Pharmacother; 2005 Nov; 39(11):1947-9. PubMed ID: 16204387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylphenidate: established and expanding roles in symptom management.
    Prommer E
    Am J Hosp Palliat Care; 2012 Sep; 29(6):483-90. PubMed ID: 22144657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Using psychostimulants in end-of-life patients with hypoactive delirium and cognitive disorders: A literature review].
    Elie D; Gagnon P; Gagnon B; Giguère A
    Can J Psychiatry; 2010 Jun; 55(6):386-93. PubMed ID: 20540834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focalin XR for ADHD.
    Med Lett Drugs Ther; 2009 Mar; 51(1308):22-4. PubMed ID: 19305368
    [No Abstract]   [Full Text] [Related]  

  • 9. [Methylphenidate augmentation of fluvoxamine for treatment-resistant depression: a case report and review literature].
    Buhagiar K; Cassar J
    Turk Psikiyatri Derg; 2007; 18(2):179-83. PubMed ID: 17566884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial.
    Pae CU; Marks DM; Masand PS; Peindl K; Hooper-Wood C; Han C; Mannelli P; Ciccone P; Patkar AA
    Clin Neuropharmacol; 2009; 32(2):85-8. PubMed ID: 19512961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coadministration of phenelzine and methylphenidate for treatment-resistant depression.
    Shelton Clauson A; Elliott ES; Watson BD; Treacy J
    Ann Pharmacother; 2004 Mar; 38(3):508. PubMed ID: 14970373
    [No Abstract]   [Full Text] [Related]  

  • 12. Psychostimulants and delirium in patients receiving palliative care.
    Keen JC; Brown D
    Palliat Support Care; 2004 Jun; 2(2):199-202. PubMed ID: 16594250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful palliation of hypoactive delirium due to multi-organ failure by oral methylphenidate.
    Morita T; Otani H; Tsunoda J; Inoue S; Chihara S
    Support Care Cancer; 2000 Mar; 8(2):134-7. PubMed ID: 10739361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Determination of the effect of the short-term administration of Pondex, methylphenidate, and placebo by various pshychological tests].
    Sindelárová M; Bojanovský J
    Act Nerv Super (Praha); 1967 Nov; 9(4):374. PubMed ID: 4388630
    [No Abstract]   [Full Text] [Related]  

  • 15. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge.
    Herrmann N; Rothenburg LS; Black SE; Ryan M; Liu BA; Busto UE; Lanctôt KL
    J Clin Psychopharmacol; 2008 Jun; 28(3):296-301. PubMed ID: 18480686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the clinical effect of short-term administration of Pondex, methylphenidate, and placebos in neuroses].
    Bojanovský J; Hánysová Z; Bouchal M; Náhunek K; Vanýsek J
    Act Nerv Super (Praha); 1967 Nov; 9(4):373. PubMed ID: 4388629
    [No Abstract]   [Full Text] [Related]  

  • 18. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparison of Pondex, methylphenidate and placebo during short term administration and the effect on serum potassium, calcium and sodium levels in neurotic patients].
    Bojanovský J; Hánysová Z
    Act Nerv Super (Praha); 1967 Nov; 9(4):375-6. PubMed ID: 4388631
    [No Abstract]   [Full Text] [Related]  

  • 20. Attention-deficit hyperactivity disorder, methylphenidate, and primary encopresis.
    Golubchik P; Weizman A
    Psychosomatics; 2009; 50(2):178. PubMed ID: 19377031
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.